// App-Quantinova.ai

P1070 : NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY

Researchers

Presenter

  • Vinod Pullarkat

Principal Investigators

  • Alexis Cruz-Chacon

  • Shane Gangatharan

  • Anton Melnyk

  • Giuseppe A. Palumbo

  • Marta Bellini

  • Srinivas K. Tantravahi

  • Qin Qin

  • Jalaja Potluri

  • Pankit Vachhani

Medical Centers

  • Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate 'G.F. Ingrassia',Università di Catania,Catania,Italia

  • Hospital Centro Comprensivo de Cancer Universidad de Puerto Rico,San Juan,Porto Rico

  • 7ASST Papa Giovanni XXIII Bergamo Italy

  • Department of Hematology and Hematopietic Cell Transplantation, City of Hope, Duarte, CA

  • Texas Oncology-Abilene,Abilene, TX,Verenigde Staten

  • Department of Hematology and Hematopietic Cell Transplantation, City of Hope, Duarte, CA

  • 7ASST Papa Giovanni XXIII Bergamo Italy

  • Hospital Centro Comprensivo de Cancer Universidad de Puerto Rico,San Juan,Porto Rico

  • Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate 'G.F. Ingrassia',Università di Catania,Catania,Italia

  • ASST Papa Giovanni XXIII,Bergamo,Италия

  • Texas Oncology-Abilene,Abilene, TX,États-unis

  • Dipartime

  • Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate 'G.F. Ingrassia',Università di Catania,Catania,Italia

  • Department of Hematology and Hematopietic Cell Transplantation, City of Hope, Duarte, CA

  • Texas Oncology-Abilene,Abilene, TX,États-unis

  • AbbVie, Inc., North Chicago, IL

  • AbbVie Inc ,North Chicago, IL,Vereinigte Staaten

  • Texas Oncology-Abilene,Abilene, TX,Verenigde Staten

  • University of Utah-Huntsman Cancer Institute, Salt Lake City, UT

  • Department of Haematology, Fiona Stanley Hospital,University of Western Australia,Perth, Western Australia,Australie

  • AbbVie Inc ,North Chicago, IL,Vereinigte Staaten

  • Department of Haematology, Fiona Stanley Hospital,University of Western Australia,Perth, Western Australia,Australie

  • AbbVie Inc ,North Chicago, IL,Estados Unidos

  • Texas Oncology-Abilene,Abilene, TX,Verenigde Staten

  • 7ASST Papa Giovanni XXIII Bergamo Italy

  • 7ASST Papa Giovanni XXIII Bergamo Italy

  • Hospital Centro Comprensivo de Cancer Universidad de Puerto Rico,San Juan,Porto Rico

  • University of Utah and Huntsman Cancer Institute,Salt Lake City,Estados Unidos

  • University of Utah and Huntsman Cancer Institute,Salt Lake City,Estados Unidos

  • AbbVie Inc ,North Chicago, IL,États-unis

  • Department of Hematology,

  • Texas Oncology-Abilene,Abilene, TX,États-unis

  • Department of Haematology, Fiona Stanley Hospita

  • Tex

  • AbbVie Inc., North Chicago, Illinois, United States

  • 7ASST Papa Giovanni XXIII Bergamo Italy

  • Hospital Centro Comprensivo de Cancer Universidad de Puerto Rico,San Juan,Porto Rico

  • University of Utah-Huntsman Cancer Institute, Salt Lake City, UT

  • O'Neal Comprehensive Cancer Center at UAB,Bi

  • University of Utah-Huntsman Cancer Institute, Salt Lake City, UT

  • AbbVie Inc ,North Chicago, IL,Stati Uniti

  • 7ASST Papa Giovanni XXIII Bergamo Italy

  • Department of Haematology, Fiona Stanley Hospital,University of Western Australia,Perth, Western Australia,Australie

Locations

  • United States

  • Puerto Rico

  • United Kingdom

  • Australia

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Thrombocytopenia

  • Myelofibrosis

  • Anemia

Biomarkers

  • N/A

Drug/Treatment

  • Navitoclax

Outcome

  • N/A

Study Design

  • Open Label

  • Multinational

  • Cohort

Phase

  • II

Study Id's

  • NCT03222609

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved